Skip to content
Subscriber Only

Zafgen Obesity Drug Trial on Hold After Patient Deaths

  • Company says patient died of blood blockages in the lungs
  • U.S. Food and Drug Administration stops trial from continuing
Corrected

Zafgen Inc. said its trial of an experimental drug to fight obesity was placed on hold by U.S. regulators after a second patient died.

The trial, in patients with a rare genetic disease called Prader-Willi syndrome that causes overeating, was a key study Zafgen needed to finish leading up to a U.S. Food and Drug Administration decision on whether to approve the drug for those patients.